期刊文献+

艾拉莫德对类风湿关节炎合并慢性间质性肺炎的近期临床疗效观察 被引量:6

Short-term Effects of Rheumatoid Arthritis Complicated with Chronic Interstitial Pneumonia Treated by Iguratimod
原文传递
导出
摘要 目的探讨艾拉莫德对类风湿关节炎(rheumatoid arthritis,RA)合并慢性间质性肺炎(interstitial pneumonia,IP)的近期临床疗效及安全性。方法回顾性分析2012年3月—2013年5月17例RA合并慢性IP患者在常规治疗疗效不明显时,联合艾拉莫德治疗的近期临床疗效及安全性。结果联合艾拉莫德治疗前ESR、CRP、RF、晨僵时间、DAS28评分均较高,联合艾拉莫德治疗后均有下降;经统计学分析,RF差异具有统计学意义(P<0.05),CRP、ESR、晨僵时间、DAS28评分差异显著(P<0.01);同时在联合艾拉莫德治疗后动脉血氧分压可得到明显改善(P<0.05),肺部HRCT未见明显改变;血液系统WBC、HB、PLT无明显降低或升高。17例患者中有1例(5.9%)患者出现上腹部不适、1例(5.9%)出现肝功能轻度异常,无感染情况出现。结论艾拉莫德对RA合并慢性IP患者具有确切的近期疗效,不良反应发生率低,合并感染情况少。 OBJECTIVE To observe the short-term effects and safety of iguratimod on rheumatoid arthritis(RA) complicated with chronic interstitial pneumonia(IP). METHODS The short-term effects and safety of 17 RA patients complicated with chronic IP(from March.2012 to May.2009), whose effects were not satisfied treated by conventional treatment and treated by iguratimod united other drugs, were retrospectively analyzed. RESULTS The ESR, CRP, RF, time of morning stiffness, DAS28 scores of the patients before treated by iguratimod were higher than after treated, the differences of RF was significant(P0.05), the differences of CRP, ESR, time of morning stiffness, DAS28 score were more significant(P0.01). The arterial partial oxygen pressure of patients could be improved(P0.05), the HRCT of lung had no obvious changes after treated; the WBC, HB, PLT had no obvious increase or decrease. Among those 17 patients, there was 1 case(5.9%) with upper abdominal discomfort, 1 case(5.9%) with mildly abnormal liver function, no infection occured. CONCLUSION Iguratimod has exactly short-term effect on RA combined with chronic IP, low incidence of adverse reactions and infection.
出处 《中国现代应用药学》 CAS CSCD 2014年第10期1275-1278,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 类风湿关节炎 间质性肺炎 临床疗效 rheumatoid arthritis interstitial pneumonia clinical efficacy
  • 相关文献

参考文献10

  • 1AAKAWA Y,TANUMA N,SHIN T,et al.A new anti-rheumatic drug,T-614,effectively suppresses the development of autoimmune encephalomyelitis [J].J Neuroimmunol,1998,89(12):35-42.
  • 2蒋叶,吕伟,余书勤,姚琳,绪广林,张锡然.艾拉莫德对脂多糖激活大鼠肺泡巨噬细胞系TNFα产生及NF-κB活性的抑制作用[J].药学学报,2006,41(5):401-405. 被引量:17
  • 3ZOU Y Q,LI Y S,DING X N,et al.The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease:a report from China [J].Rheumatol Int,2012,32(3):669-673.
  • 4苏毅,李源,王乐乐.特发性间质性肺炎38例的影像学特征[J].安徽医学,2010,31(10):1214-1217. 被引量:8
  • 5TANAKA K,YAMAMOTO T,AIKAWA Y,et al.lnhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice [J].Rheumatology(oxford),2003,42(11):1365-1371.
  • 6张源潮,王峰,王威严,于成成,杨清锐.类风湿关节炎治疗新药艾拉莫德[J].世界临床药物,2013,34(2):65-69. 被引量:30
  • 7李秋霞,古洁若.艾拉莫德对小鼠成纤维细胞分泌胶原的影响[J].医学研究杂志,2009,38(10):44-47. 被引量:4
  • 8MUCKE H A.Iguratimod:a new disease-modifying antirheu- matic drug [J].Drugs Today(Barc),2012,48(9):577-586.
  • 9LU L J,BAO C D,DAI M,et al.Multicenter,randomized,double-blind,controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate [J].Arthritis Rheum,2009,61(7):979-987.
  • 10ISHIGURO N,YAMAMOTO K,KATAYAMA K,et al.Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate:a randomized,double- blind,placebo-controlled trial [J].Mod Rheumatol,2013,23(3):430-409.

二级参考文献19

共引文献51

同被引文献53

  • 1蒋叶,吕伟,余书勤,姚琳,绪广林,张锡然.艾拉莫德对脂多糖激活大鼠肺泡巨噬细胞系TNFα产生及NF-κB活性的抑制作用[J].药学学报,2006,41(5):401-405. 被引量:17
  • 2焦志军,王文红,李晶,陈蕾,尤海燕,汪毅,周光炎.类风湿关节炎患者外周血单个核细胞Notch及其配体表达[J].现代免疫学,2007,27(6):477-480. 被引量:7
  • 3Saag K G,Teng G G,Patkar N M,et al.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis[J].Arthritis Rheum,2008,59(6):762.
  • 4Ju J H,Kim S I,Lee J H,et al.Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis[J].Arthritis Rheum,2007,56(6):2094.
  • 5Perez-Alvarez R,Perez-de-Lis M,Diaz-Lagares C,et al.Interstitial lung disease induced or exacerbated by TNF-αtargeted therapies:analysis of 122 cases[J].Semin Arthritis Rheum,2011,41(2):256.
  • 6Aletaha D,Neogi T,Silman A J,et al.2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J].Arthritis Rheum,2010,62(9):2569.
  • 7Helbich T H,Heinz-Peer G,Eichler I,et al.Cystic fibrosis:CT assessment of lung involvement in children and adults[J].Radiology,1999,213(2):537.
  • 8Kelly C A,Saravanan V,Nisar M,et al.Rheumatoid arthritis-related interstitial lung disease:associations,prognostic factors and physiological and radiological characteristics-a large multicentre UK study[J].Rheumatology(Oxford),2014,53(9):1676.
  • 9Norton S,Koduri G,Nikiphorou E,et al.A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome[J].Rheumatology(Oxford),2013,52(1):99.
  • 10Sheykh Zh V,Krutskevich A O,Drebushevskiy N S,et al.Pulmonary cytotoxicity induced by bleomycin and methotrexate[J].Vestn Rentgenol Radiol,2015,(3):46.

引证文献6

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部